首页> 外文期刊>World Journal of Gastroenterology >Risk factors for liver-related mortality in chronic hepatitis C patients: A deceased case-living control study
【24h】

Risk factors for liver-related mortality in chronic hepatitis C patients: A deceased case-living control study

机译:慢性丙型肝炎患者肝相关死亡的危险因素:病例死亡对照研究

获取原文
       

摘要

AIM: To investigate the risk factors for liver-related mortality in chronic hepatitis C (CHC) patients. METHODS: All deceased CHC inpatient data were collected from the Beijing 302 Hospital clinical database, which includes more than 8250 CHC inpatients during the period from 2002 to 2012. The controls were matched to cases by age (± 2 years), sex and date of hospital admission (within the same year). Potential risk factors were included for the evaluation, and odds ratios (OR) and 95%CI were estimated using univariate (unadjusted) and multivariate (adjusted OR, AOR) conditional logistic regression. All statistical tests were two-sided. P values RESULTS: Based on examinations of 144 CHC-related deceased cases and 576 controls, we found that antiviral therapy with interferon-α was associated with a 47% decrease in the risk of hepatic mortality (AOR = 0.53, 95%CI: 0.28-0.99, P = 0.048). Additionally, the initial diagnostic stage of the disease (AOR = 2.89, 95%CI: 1.83-4.56 and P P P = 0.001), hypertension (AOR = 1.76, 95%CI: 1.09-2.82, P = 0.020), alcohol consumption (AOR = 1.73, 95%CI: 1.03-2.81, P = 0.037) and HBsAg positivity (AOR = 22.28, 95%CI: 5.58-89.07, P CONCLUSION: This study indicates that interferon-α treatment, the stage at the initial diagnosis of the disease and comorbidities are all independent risk factors for liver-related mortality in CHC patients.
机译:目的:探讨慢性丙型肝炎(CHC)患者肝相关死亡的危险因素。方法:从北京302医院临床数据库中收集所有已故的CHC住院患者数据,其中包括2002年至2012年期间的8250多名CHC住院患者。对照人群按照年龄(±2岁),性别和患病日期进行匹配。住院(同年)。评估中包括潜在的风险因素,并使用单变量(未调整)和多元(调整后的OR,AOR)条件对数回归评估比值比(OR)和95%CI。所有统计检验都是双面的。 P值结果:根据对144例与CHC相关的死者和576例对照的检查,我们发现抗干扰素-α的抗病毒治疗可使肝死亡风险降低47%(AOR = 0.53,95%CI:0.28 -0.99,P = 0.048)。此外,疾病的初始诊断阶段(AOR = 2.89,95%CI:1.83-4.56和PPP = 0.001),高血压(AOR = 1.76,95%CI:1.09-2.82,P = 0.020),饮酒(AOR = 1.73,95%CI:1.03-2.81,P = 0.037)和HBsAg阳性(AOR = 22.28,95%CI:5.58-89.07,P)结论:这项研究表明干扰素-α治疗是初始确诊的阶段。该疾病和合并症都是CHC患者肝脏相关死亡率的独立危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号